English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Aberrant activation of MAP kinase signaling pathway and loss of tumor suppressor LKB1 have been implicated in lung cancer development and progression. Although oncogenic KRAS mutations are frequent, BRAF mutations (BRAF V600E ) are found in 3% of human non-small cell lung cancers. Contrary to KRAS mutant tumors, BRAF V600E -induced tumors are benign adenomas that fail to progess. Interestingly, loss of tumor supressor LKB1 coexists with KRAS oncogenic mutations and synergizes in tumor formation and progression, however, its cooperation with BRAF V600E  oncogene is unknown. Our results describe a lung cell population in neonates mice where expression of BRAF V600E  leads to lung adenoma development. Importantly, expression of BRAF V600E  concomitant with the loss of only a single-copy of Lkb1, overcomes senencence–like features of BRAF V600E -mutant adenomas leading malignization to carcinomas. These results posit LKB1 haploinsufficiency as a risk factor for tumor progression of BRAF V600E  mutated lung adenomas in human cancer patients.

Lkb1 Loss Promotes Tumor Progression of BRAFV600E-Induced Lung Adenomas